1	Contribution of leukocyte telomere length to major cardiovascular diseases onset:
2	phenotypic and genetic insights from a large-scale genome-wide cross-trait
3	analysis
4	
5	Jun Qiao ^{1#} , Qian Wang ^{2#} , Yuhui Zhao ^{2#} , Minjing Chang ¹ , Liuyang Cai ¹ , Feng Liu ³ , Kaixin Yao ² ,
6	Leilei Zheng ² , Ning Tan ⁴ , Pengcheng He ⁴ , Anil G. Jegga ^{5,6,7} , Siim Pauklin ^{7*} , Lei Jiang ^{4*} , Yining
7	Yang ^{8,9*} , Yuliang Feng ^{1*}
8	¹ Department of Pharmacology, School of Medicine, Southern University of Science and
9	Technology, Shenzhen, China.
10	² Shanxi Key Laboratory of Big Data for Clinical Decision, Shanxi Medical University, Taiyuan,
11	China.
12	³ Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and
13	Musculoskeletal Sciences, University of Oxford, Headington, Oxford, UK.
14	⁴ Department of Cardiology, Guangdong Cardiovascular Institute, Guangdong Provincial
15	People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University,
16	Guangzhou, China.
17	⁵ Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, USA.
18	⁶ Department of Computer Science, University of Cincinnati College of Engineering,
19	Cincinnati, USA.
20	⁷ Department of Internal Medicine, College of Medicine, University of Cincinnati, Cincinnati,
21	USA.
22	⁸ Department of Cardiology, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi,
23	China.
24	⁹ Xinjiang Key Laboratory of Cardiovascular Homeostasis and Regeneration Research, Urumqi,
25	China.
26	[#] These authors contributed equally to this work.
27	
28	*Correspondence to:
29	Yuliang Feng MD, PhD
30	Associate Professor

- 31 Department of Pharmacology, School of Medicine; Southern University of Science and
- 32 Technology, Shenzhen, Guangdong, 518055, China.
- 33 Tel:+86 (755)-88012564
- 34 Email: <u>fengyl@sustech.edu.cn</u>
- 35
- 36 Yining Yang MD, PhD
- 37 Professor
- 38 Department of Cardiology, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, ,
- 39 Xinjiang Uygur Autonomous Region, 830000, China.
- 40 Xinjiang Key Laboratory of Cardiovascular Homeostasis and Regeneration Research, Urumqi,
- 41 Xinjiang Uygur Autonomous Region, 830001, China.
- 42 Tel:+86 (0991)-960200
- 43 Email: yangyn5126@xjrmyy.com
- 44
- 45 Lei Jiang MD, PhD
- 46 Associate Professor
- 47 Department of Cardiology; Guangdong Cardiovascular Institute, Guangdong Provincial
- 48 People's Hospital (Guangdong Academy of Medical Sciences); Southern Medical University,
- 49 Guangzhou, Guangdong, 510080, China.
- 50 Tel:+86 (20)-83837812
- 51 Email: jianglei0731@gmail.com
- 52
- 53 Siim Pauklin PhD
- 54 Group leader and CRUK Career Development Fellow
- 55 Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and
- 56 Musculoskeletal Sciences, University of Oxford, Headington, Oxford OX3 7LD, UK.
- 57 Tel: +44 (0)-1865226492
- 58 Email: siim.pauklin@ndorms.ox.ac.uk
- 59

60 Abstract

61 Telomere shortening, a marker of cellular aging and genomic instability, has been 62 epidemiologically linked to an increased risk of various cardiovascular diseases (CVDs). 63 However, shared genetic determinants involved in these associations remain unclear. We 64 composed an atlas of the shared genetic associations between leukocyte telomere length (LTL) 65 and six major CVDs by investigating shared genetic elements, encompassing SNPs, genes, 66 biological pathways, and protein targets with pleiotropic implications. Extensive genetic 67 overlaps beyond genetic correlations were observed, but no causal relationships were 68 established. We identified 248 independent pleiotropic genomic risk loci, implicating 50 unique 69 genes in two or more trait pairs, especially the SH2B3 gene, which was further validated by a 70 proteome-wide Mendelian Randomization study. Functional analysis demonstrated a link to 71 both DNA biosynthetic processes and telomere maintenance mechanisms. These findings 72 suggest a genetic link between LTL and CVDs, highlighting a shared genetic basis crucial for 73 developing future interventions and therapeutic targets.

74 Introduction

75 Telomeres, DNA-protein complexes located at the ends of linear eukaryotic chromosomes, play a critical role in genome protection and act as indicators of biological aging.¹. With each cell 76 77 division, telomere progressively shortens due to the increased rate of somatic cell turnover and 78 aging, eventually reaching a critical threshold known as the Hayflick limit. Beyond this point, 79 DNA damage and cellular senescence begin, marking the onset of genomic instability. This 80 process of telomere attrition is particularly relevant in cardiovascular diseases (CVDs), where 81 the accumulation of senescent cells leads to tissue inflammation and matrix degradation. These 82 changes contribute to the thinning of the fibrous cap, thereby heightening the risk of CVDs. 83 Previous meta-analyses have identified an inverse association between leukocyte telomere 84 length (LTL) and the risk of most CVDs, particularly coronary artery disease (CAD) and heart 85 failure (HF), independent of conventional vascular risk factors, although the relationship with other CVDs remains more ambiguous²⁻⁴. This body of evidence highlighted the potential 86 87 impact of LTL on the development and progression of various CVDs. Moreover, inflammation 88 and oxidative stress central to the pathogenesis of CVDs further accelerate telomere shortening 89 and cellular senescence. This complex interplay highlights the significant connection between 90 LTL and CVDs, underscoring the need for further research into their joint mechanisms.

91

92 Previous epidemiological studies have demonstrated that telomere shortening was associated 93 with an elevated risk of various CVDs. One plausible explanation is the overlap of genetic 94 determinants for LTL and CVDs. LTL varies significantly among individuals from birth and throughout their lifespan, exhibiting high heritability with estimates ranging from 44% to 95 86%^{5,6}. The largest genome-wide association study (GWAS) to date on LTL, using UK Biobank 96 97 data, identified 138 associated loci, revealing links between genetically determined LTL^7 and 98 multiple CVD phenotypes, such as CAD. The recent accessibility of GWAS data for a diverse spectrum of CVD phenotypes offers a valuable opportunity to investigate the genetic basis 99 between LTL and CVDs⁸⁻¹³. The shared genetic foundations may be understood as genetic 100 101 variants influencing multiple complex phenotypic traits through both vertical and horizontal 102 pleiotropy. Briefly, vertical pleiotropy emerges when a genetic variation affects one phenotype, 103 which in turn influences the occurrence of another phenotype—a concept primarily addressed

104 by Mendelian Randomization (MR) studies. Several previous MR studies have suggested that 105 the associations of shorter LTL with CAD and Stroke were genetically causal, although evidence for an association with AF and HF was less certain, presenting confused results¹⁴⁻¹⁷. 106 107 The causality of the relationships between LTL and other CVD phenotypes has not been 108 adequately demonstrated. Conversely, horizontal pleiotropy occurs when a single genetic 109 variation simultaneously impacts multiple phenotypes, which may highlight potential shared 110 biological pathways among complex traits. Recent advances in genomics statistical tools have 111 unveiled the vital role of horizontal pleiotropy beyond vertical pleiotropy in shared genetic foundations across complex traits, as highlighted in a study by Gong *et al*¹⁸. However, prior 112 113 research on horizontal pleiotropy has primarily concentrated on exploring the relationship between LTL and severe mental disorders¹⁹. Therefore, in light of the widespread associations 114 115 reported in epidemiological studies and the existing evidence of a shared genetic basis 116 LTL and CVDs, the necessity for a comprehensive, large-scale analysis is clear.

117

118 Recognizing the knowledge gap, our study aims to provide a thorough analysis of shared 119 genetic architectures between LTL and CVDs by encompassing the unprecedentedly large 120 available GWAS datasets in individuals of European ancestry. First, by charting the landscape 121 of genetic overlap beyond genetic correlation, we provide more granular insights into the 122 unique and shared genetic architectures between LTL and CVDs. Then, we employed 123 statistical techniques to capture diverse forms of genetic pleiotropy, followed by thorough analyses 124 to link the genomic findings to biological pathways, yielding profound implications for 125 conceptualizing shared genetic risk for both LTL and CVDs.

126

127 **Results**

128 Genetic overlap beyond genetic correlation between LTL and six major CVDs

Following the harmonization and filtering of SNPs shared across GWAS summary statistics, we employed cross-trait linkage disequilibrium (LD) score regression (LDSC) to calculate SNP-based heritability (h^2_{SNP}) and to assess genome-wide genetic correlation (r_g) between LTL and six major CVDs. Univariate LDSC revealed that the estimated h^2_{SNP} for LTL was 2.76% (SE = 0.30%). On average, the estimated h^2_{SNP} was nearly threefold higher for AF

 $(h_{SNP}^2 = 2.50\%, SE = 0.33\%)$, CAD $(h_{SNP}^2 = 3.25\%, SE = 0.19\%)$, and VTE $(h_{SNP}^2 = 1.82\%, SE$ 134 = 0.23%), in comparison to HF (h_{SNP}^2 = 0.80%, SE = 0.06%), PAD (h_{SNP}^2 = 0.94%, SE = 135 0.13%), and Stroke ($h^2_{SNP} = 0.60\%$, SE = 0.05%) (Supplementary Fig. 1a and Supplementary 136 137 Table 2a). The results of bivariate LDSC indicated a range of weak to moderate genome-wide 138 r_g between LTL and CVDs, excluding LTL-AF. Notably, the most pronounced negative r_g were observed for LTL-PAD ($r_g = -0.250$, SE= 0.040, $P = 3.83 \times 10^{-10}$) and CAD ($r_g = -0.171$, 139 SE = 0.025, $P = 4.65 \times 10^{-12}$), while smaller but statistically significant r_g were noted for 140 Stroke ($r_g = -0.104$, SE = 0.037, $P = 4.60 \times 10^{-3}$) and VTE ($r_g = -0.072$, SE = 0.025, P = -0.025, P =141 142 4.20×10^{-3}). LTL was only moderately genetically correlated to HF ($r_g = -0.145$, SE = 0.037, P 143 = 8.20×10⁻⁵). In contrast, no significant r_g was observed between LTL and AF (Supplementary 144 Fig. 1b and Supplementary Table 2b). Although genome-wide r_g offered valuable insight into 145 the genetic overlap between phenotypes, it could not distinguish genetic overlap resulting 146 from a mixture of concordant and discordant effects from the absence of genetic overlap, 147 potentially yielding an estimated r_g near zero in both scenarios. Therefore, using multiple 148 methods with different model assumptions to identify and understand this "missing 149 dimension" of genetic overlap was essential for comprehensively characterizing the shared 150 genetic foundations across phenotypes.

151

Despite minimal r_g estimated by LDSC, the causal mixture modeling approach (MiXeR) was 152 153 then applied to elucidate extensive genetic overlap beyond genetic correlation by determining 154 the number of overlapping variants between LTL and six major CVDs, irrespective of the 155 direction of their effects. Univariate MiXeR revealed that LTL exhibited a lower degree of 156 polygenicity (N = 0.380K, SD = 0.026K). Among the six major CVDs, HF (N = 2.305K 157 'causal' variants explaining 90% of HF's h_{SNP}^2 , SD = 0.213K) was the most polygenic, 158 followed by CAD (N = 1.528K, SD = 0.311K) and Stroke (N = 1.055K, SD = 0.117K). VTE, 159 PAD, and AF demonstrated lower polygenicity, associated with 0.308K to 0.504K variants at 90% h^2_{SNP} (Supplementary Table 3a). These findings highlighted a pattern of polygenicity 160 161 distinct from h^2_{SNP} estimates.

162

163 The result of bivariate MiXeR revealed substantial but distinct patterns of polygenic overlap

164 between LTL and CVDs. Given the low polygenicity of LTL and these CVD phenotypes 165 (including AF, PAD, and VTE), LTL was found to share less proportion of causal variants 166 with these CVDs, ranging from 18.30% in AF to 22.63% in PAD. However, relatively large 167 genetic overlaps were also observed between LTL and these CVDs (Fig. 2a, Supplementary 168 Fig. 2, Supplementary Table 3b). For example, polygenic overlap between LTL and PAD was 169 particularly striking (Dice coefficient $\Box = \Box 0.229$, SD = 0.015), with 0.086K (SD $\Box = \Box 0.007K$) 170 shared variants, representing 22.63% LTL-influencing variants and 23.24% PAD-influencing 171 variants, consistent with the strongest negative genome-wide genetic correlation ($r_g = -0.223$, 172 SE = 0.014) and genetic correlation of shared variants ($r_e s = -0.970$, SE = 0.022). A total of 173 0.069K (SD $\equiv 0.019$) variants were estimated to be shared between LTL and AF, 174 representing 18.30% LTL-influencing variants and 13.79% AF-influencing variants, despite 175 weak negative genetic correlation. This pattern of extensive genetic overlap but weak r_{e} 176 indicated a predominance of mixed effect directions, supported by the MiXeR-estimated 177 proportion of shared 'causal' variants with concordant effects (0.416, SD = 0.029). 178 Considering the low polygenicity of LTL and high polygenic diseases such as CAD, HF, and 179 Stroke, significant disparities were observed in the number of shared and unique "causal" 180 variants. In particular, MiXeR estimated that of the 0.380K LTL-influencing variants, 48.69%, 181 39.82%, and 28.07% also influence HF, CAD, and Stroke, respectively. For example, LTL and 182 HF shared the largest number of variants (N = 0.185K, SD = 0.024K), with many more 183 unique variants of HF (N = 2.12K, SD = 0.208K) than unique variants of LTL (0.195K, SD = 184 0.030K), representing 48.69% LTL-influencing variants and 8.02% HF-influencing variants. 185 While they were moderately correlated at the genome-wide level ($r_g = -0.180$, SE = 0.017), 186 shared variants were strongly correlated ($r_{es} = -0.913$, SE = 0.087). A similar, although less 187 pronounced, relationship was evident in LTL-CAD and LTL-Stroke. Furthermore, the 188 overlapping variants demonstrated a low level of effect direction concordance, highlighting 189 the prevalence of mixed effect directions between LTL and CVDs. These observations 190 suggested that the extent of polygenic overlap between LTL and CVDs were likely 191 underestimated by genome-wide genetic correlations (Fig. 2b).

192

193 Local genetic correlations provide a more effective means of capturing genetic associations

194 with mixed effect directions. Specifically, a pair of traits may display no genome-wide r_{e} due 195 to an equal number of positive and negative (opposite effect directions) local genetic 196 correlations with comparable magnitudes. To prevent the potential masking of local genetic 197 correlations when evaluating r_{e} at the genome-wide level, we applied Local Analysis of 198 [co]Variant Annotation (LAVA) to perform local genetic correlations (loc- r_{es}) between LTL 199 and six major CVDs at loci, where both phenotypes had heritability estimates significantly 200 different from zero (Supplementary Table 4). Overall, 45 local genomic regions were found 201 significant for bivariate analysis after correcting for multiple testing using FDR (FDR < 0.05, 202 Fig. 2a and Supplementary Table 5), with 62% and 38% of the partitions showing negative 203 and positive loc- $r_e s$, respectively. Corroborating the MiXeR findings, LAVA estimated 204 correlated loci of LTL-PAD (2 positively correlated and 3 negatively correlated loci), 205 LTL-VTE (3 positively correlated and 4 negatively correlated loci), and LTL-AF (9 positively 206 correlated and 4 negatively correlated loci), adding further support for a shared genetic basis. 207 Local correlations for LTL-CAD, comprising 14 negatively and 3 positively correlated loci, 208 and LTL-Stroke, with 3 negatively correlated loci and none positively correlated, were 209 inconsistent with the mixed effect directions estimated by MiXeR. The absence of significant 210 loci between LTL and HF may be attributed to LAVA's propensity for identifying loci with 211 extreme correlations, in contrast to MiXeR, thereby highlighting loci more likely to be 212 statistically significant.

213

214 Interestingly, our investigation also identified a solitary region (LD block 1,841 on 215 chromosome 12, ranges from 111,592,382 to 113,947,983) displaying significant correlations 216 for a majority of the trait pairs, with uniform negative correlation values between -0.530 and 217 -0.692. Subsequent analyses utilizing Hypothesis Prioritisation in Multi-trait Colocalization 218 (HyPrColoc) revealed robust colocalization evidence for this locus between LTL and all 219 CVDs, excluding AF, HF and PAD, with a posterior probability (PP) higher than 0.7, which 220 encompassed the shared causal SNP (rs10774625, an intronic variant of the ataxin 2 (ATXN2) 221 gene on 12q24.12). The ATXN2 rs10774625 polymorphism has been associated with various 222 CVDs, notably CAD, alongside cardiometabolic markers such as blood pressure and blood lipids^{20,21}. 223

224

225 The Causal inference between LTL and six major CVDs

226 Despite these findings substantiating a shared genetic foundation between LTL and six major 227 CVDs, there was uncertainty in relation to whether the complex interplay predominantly 228 reflected horizontal pleiotropy or potentially involved a causal relationship (referred to as 229 'vertical pleiotropy'). Mendelian randomization (MR) harnesses vertical pleiotropy to deduce 230 potential causal relationships, excluding any SNPs indicative of horizontal pleiotropy. 231 Therefore, latent causal variable (LCV) analysis was utilized to elucidate the possible causal 232 relationships underlying the genetic correlations observed. Notably, none of the trait pairs 233 demonstrated tendencies indicative of partial genetic causation (Supplementary Fig. 3a, 234 Supplementary Table 6a). To ascertain the reproducibility of the partial causal associations 235 between trait pairs, we utilized the Latent Heritable Confounder Mendelian Randomization 236 (LHC-MR) approach, taking into account factors such as sample overlap, bidirectional causal 237 associations, and unobserved heritable confounders. Consistently, no evidence was found to 238 support a putative causal effect of LTL on CVDs (Supplementary Fig. 3b, Supplementary 239 Table 6b). Only the possible weak positive causal impact of CAD on LTL was observed, yet 240 lacked confirmation from conventional bidirectional MR analyses (Supplementary Table 6c), 241 emphasizing the need for cautious interpretation. Overall, MR analysis revealed that the 242 shared genetic foundation between LTL and CVDs cannot be ascribed to vertical pleiotropy.

243

244 Pleiotropic genomic loci identified for LTL and CVDs

245 The observed comorbidity between LTL and six major CVDs suggests that instead of a 246 predominance of trait-specific risk variants, there may be a set of pleiotropic variants 247 influencing the risk of both LTL and CVDs (i.e., horizontal pleiotropy). To investigate this, 248 we employed the Pleiotropic Analysis under a Composite Null Hypothesis (PLACO) to 249 pinpoint potential pleiotropic variants shared between LTL and CVDs, resulting in the 250 identification of 12,604 SNPs comprising 10,008 unique variants. Functional Mapping and 251 Annotation (FUMA) further delineated 248 independent genomic risk loci as pleiotropic, 252 spanning 122 unique chromosomal regions (Fig. 3, Supplementary Fig 4, Supplementary 253 Table 7). Among these, 194 loci were associated with LTL and 80 loci with CVDs. In

254 aggregate, 32 loci overlapped between LTL and CVDs, accounting for 16.49% and 40.00% of 255 the total number of loci linked to these respective categories. A total of 188 pleiotropic loci 256 exhibited genetic signals for multiple trait pairs, with 74 of them (39.36%) spanning 16 257 unique chromosomal regions, demonstrating this phenomenon in over half of the investigated 258 trait pairs. For example, the pleiotropic locus 16q22.1 (mapped gene: TMED6) was jointly 259 associated with LTL and all CVDs. A mixture of concordant and discordant allelic effects 260 existed in these pleiotropic loci. Remarkably, the selected effect alleles at the top SNPs within 261 or near 117 loci (47.2%) exhibited inconsistent effects on two traits within a pair of traits. 262 Essentially, these variants may concurrently increase LTL and diminish the risk of developing 263 CVDs, aligning with their robust genome-wide genetic correlation. Conversely, the remaining 264 SNPs demonstrated concordant associations with both LTL and CVDs, implying that these 265 SNPs might influence the risk of both traits in the same direction.

266

267 ANNOVAR category annotation of candidate SNPs shared between LTL and CVDs revealed 268 that 67 (27.0%) were in intergenic regions, 114 (45.9%) were in intronic regions, and only 14 269 (5.6%) were in exonic regions. For example, the index SNP rs1566452 at 16q22.1 locus $(P_{PLACO} = \Box 4.46 \times 10^{-8}$ for LTL-HF) was associated with artery coronary and artery tibial 270 eQTLs ($P_{Artery_Coronary} = 4.06 \times 10^{-5}$, $P_{Artery_Tibial} = 3.32 \times 10^{-10}$, Supplementary Table 9) for WW 271 272 domain-containing E3 ubiquitin protein ligase 2 (WWP2) gene encoding one of the E3 273 ubiquitin ligases, which critically participate in the development and progression of cardiovascular diseases²². Besides, numerous ubiquitin E3 ligases have also been documented 274 275 to promote the degradation of human telomerase reverse transcriptase (hTERT), thereby 276 reducing telomerase activity and potentially leading to decreased telomere length²³. 277 Furthermore, we identified 21 top SNPs with combined annotation-dependent deletion 278 (CADD) scores exceeding 12.37, and 7 mRNA exonic variants had higher CADD scores, 279 which was indicative of potentially deleterious effects. Notably, rs11556924 within the zinc 280 finger C3HC-type containing 1 (ZC3HC1) gene represents an exonic non-synonymous variant 281 with a CADD score of 28 (variants with scores surpassing 20 are predicted to be among the 282 1.0% most deleterious substitutions in the human genome). Furthermore, nine SNPs were 283 assigned RegulomeDB scores of 1f, 1d, or 1a, indicating a likely influence on binding sites.

We followed up this finding using the GTEx database to investigate the gene regulatory effects. For example, rs11779558 at 8p21.3 locus was significantly associated with eQTL functionality in artery tibial ($P_{Artery Tibial} = 5.79 \times 10^{-5}$) for exportin 7 (*XPO7*) gene.

287

288 Colocalization analysis further revealed 22 out of 248 potential pleiotropic loci with PP.H4 289 greater than 0.7, wherein 14 top SNPs at the corresponding loci were identified as 290 candidate-shared causal variants (Fig. 3, Supplementary Fig. 5, Supplementary Table 7). 291 Notably, the 12q24.12 locus, identified as pleiotropic for all correlated trait pairs except for 292 LTL-AF, exhibited strong evidence of colocalization between these trait pairs (PP.H4 ranging 293 from 0.729 to 0.998). HyPrColoc analysis further revealed strong colocalization evidence for 294 this locus between LTL and all CVDs except AF and PAD, with a PP exceeding 0.7, which 295 encompassed rs10774625 (an intronic variant of the ATXN2 gene on 12q24.12) as the 296 potential shared causal variant. Moreover, 40 pleiotropic loci were identified with PP.H3 297 exceeding 0.7, indicating the possibility of different causal variants within these loci.

298

299 Pleiotropic genes associated with LTL and multiple CVDs

300 Despite the success of the above analyses in identifying disease risk loci, the biological 301 significance of most identified variants remains unknown. To achieve a more comprehensive 302 understanding of how genetic variation influences disease risk, we adopted approaches 303 integrating SNPs across a spectrum of association significance to construct a cohort of 304 predicted genes that could subsequently be mapped to functional pathways for analysis. We 305 employed two distinct strategies for mapping SNPs to genes: Firstly, a genome-wide 306 gene-based association study (GWGAS) in MAGMA and positional mapping in FUMA were 307 utilized, mapping SNPs to genes based on their physical position in the genome. Secondly, an 308 eQTL-informed GWGAS in e-MAGMA and eQTL mapping in FUMA were employed to 309 map SNPs to genes through their eQTL associations.

310

MAGMA analysis, utilizing 557 potential pleiotropic genes located within or overlapping with 248 pleiotropic loci, identified 478 significant pleiotropic genes (323 unique), in which 244 genes were detected in two or more trait pairs (Fig. 4, Supplementary Table 11). For

314 example, SH3PXD2A, SH2B3, BRAP, ATXN2, PTPN11, NAA25, ALDH2, and ACAD10 were 315 identified as significant pleiotropic genes in five pairs of traits. Remarkably, seven of eight 316 genes (excluding SH3PXD2A) were located on the 12q24.12 locus, identified in all trait pairs 317 except for LTL-AF. Of the pleiotropic genes identified, 98 (20.50%) were novel for LTL and 318 258 (53.97%) for CVDs. Only one pleiotropic gene, CD19 molecule (CD19), had not 319 previously been reported to be associated with both traits. Furthermore, 472 genes (98.74%) 320 identified by MAGMA were confirmed by FUMA positional mapping (Supplementary Table 321 9).

322

323 To pinpoint tissues potentially integral to the biological processes of LTL and six major CVDs, 324 we utilized LDSC-SEG for tissue-specific enrichment analysis using single trait GWAS 325 summary statistics. Regarding multi-tissue gene expression, we found that expressions of 326 LTL-associated loci were significantly enriched in spleen tissues, surpassing an FDR > 0.05327 threshold (Fig. 5, Supplementary Table 14). Additionally, AF showed significant enrichment in 328 heart-related tissues, including heart left ventricle and heart atrial appendage, while CAD 329 demonstrated enrichment in artery-related tissues, such as artery tibial, artery aorta, and artery 330 coronary. Conversely, no significant tissue-specific enrichment was observed for VTE, HF, 331 PAD, and Stroke. These findings were corroborated by multi-tissue chromatin interaction 332 results.

333

334 Given that MAGMA assigns SNPs to the nearest genes based on arbitrary genomic windows, 335 and considering that the effects of a locus don't always operate through the nearest gene, a 336 critical need remains to functionally link SNPs to genes (e.g., through genetic regulation) to 337 enhance our understanding of potential underlying mechanisms. Consequently, e-MAGMA 338 was conducted to uncover functional gene associations potentially overlooked by the 339 proximity-based SNP assignment in MAGMA, thereby illuminating alternative causal 340 pathways from SNPs to traits. E-MAGMA analysis revealed 1,844 significant tissue-specific 341 pleiotropic genes (419 unique) after Bonferroni correction, each strongly enriched in at least 342 one tissue (Supplementary Table 15). Of these, 918 tissue-specific pleiotropic genes (75 343 unique) were significantly identified across multiple trait-related tissues in at least two trait

344 pairs. For example, MAPKAPK5, TMEM116, HECTD4, ALDH2, and ACAD10, all located on 345 the 12q24.12 locus, were recognized as significant tissue-specific pleiotropic genes in all trait 346 pairs except for LTL-AF. Notably, transmembrane protein 116 (*TMEM116*) gene was found to 347 be highly tissue-specific, showing enrichment in eight trait-related tissues, including artery 348 tibial, artery coronary, adipose visceral (omentum), adipose subcutaneous, heart atrial 349 appendage, heart left ventricle, liver, and whole blood. TMEM116 encoded a transmembrane 350 protein involved in blood coagulation and had been identified as a potential risk gene for coronary atherosclerosis in previous studies²⁴. However, its relationship with LTL remained 351 352 less understood. In comparison with the transcriptome-wide association study (TWAS) results 353 for single-trait GWAS, we identified 415 tissue-specific pleiotropic genes as novel for LTL 354 and 851 for CVDs (Supplementary Table 16). Finally, we successfully replicated 1,117 genes 355 (60.57%) using FUMA eQTL mapping (Supplementary Table 9).

356

357 Finally, 289 pleiotropic genes (207 unique) were jointly identified by MAGMA and 358 e-MAGMA analysis, in which 50 unique genes were detected in 2 or more trait pairs, further 359 suggesting the tissue specificity of these pleiotropic genes (Supplementary Table 11). For 360 example, ACAD10 (12q24.12), ALDH2 (12q24.12), HECTD4 (12q24.12), MAPKAPK5 361 (12q24.12), NAA25 (12q24.12), SH2B3 (12q24.12), TMEM116 (12q24.12), SERPINF1 362 (17p13.3), TMED6 (16q22.1), and XPO7 (8p21.3) were identified as significant pleiotropic 363 genes in more than half of the trait pairs. Remarkably, two of ten genes (including ALDH2 364 and ACAD10) were located at the 12q24.12 locus, identified in five pairs of traits except for 365 LTL-AF. Acyl-CoA dehydrogenase family member 10 (ACAD10), a gene encoding an 366 enzyme crucial for fatty acid beta-oxidation in mitochondria, critically regulates cellular lipid synthesis with significant expression in the human brain²⁵. Previous data show that 367 368 homozygous loss of function of ACAD10 results in perturbed lipid synthesis that potentially 369 influences the development of CVDs, whereas common gene variants have been associated 370 with CAD, Stroke, and hypertension (a common CVD risk factor). Additionally, aldehyde 371 dehydrogenase 2 family member (ALDH2) gene encoding a vital mitochondrial enzyme 372 critical for cardiac function, has been associated with exacerbated myocardial remodeling and 373 contractile dysfunction in aging. This association is possibly through mitochondrial damage

374 mediated by the AMPK/Sirt1 pathway.

375

376 Shared biological pathways between LTL and six major CVDs

377 To investigate the concept that a group of genes might work collectively to fulfill specific 378 biological functions through shared pathways or functional category enrichments, we 379 employed various analytical strategies, including gene-set analysis of genes identified via 380 MAGMA and functional enrichment analysis targeting tissue-specific genes. After rigorously 381 adjusting for 7,744 gene sets (biological processes sets from the Molecular Signatures 382 Database (MSigDB, v.2023.1; C5: GO BP)), we noted minimal overlap in gene sets between 383 LTL and six major CVDs. Only three gene sets associated with chromatin organization, the 384 negative regulation of nucleobase-containing compound metabolic processes, and the 385 negative regulation of miRNA maturation were enriched across several trait pairs, and no 386 gene set demonstrated significant enrichment across more than one trait (Supplementary 387 Table 17a). Remarkably, massive genes shared between LTL and AF were most significantly 388 linked to the 'negative regulation of the nucleobase-containing compound metabolic process.' 389 Subsequently, we identified several biological processes overrepresented among the 50 390 pleiotropic genes detected by MAGMA and e-MAGMA analysis in 2 or more trait pairs 391 shared between LTL and CVDs using the ToppGene Functional Annotation tool (ToppFun) 392 (Supplementary Fig. 6, Supplementary Table 17b). All identified significant biological 393 processes, with the exception of the DNA biosynthetic process, were directly associated with 394 telomere maintenance processes such as 'telomere maintenance via telomerase,' 'telomere 395 maintenance via telomere lengthening,' 'telomere capping,' and 'telomere organization.' 396 Interestingly, the nucleobase-containing compound metabolic process identified in the 397 MAGMA gene-set analysis encompassed both DNA biosynthetic processes and telomere 398 maintenance mechanisms, implying a key role in shared biological pathways between LTL 399 and CVDs.

400

401 Shared causal proteins between LTL and six major CVDs

We undertook a comprehensive analysis of the Mendelian randomization (MR) associationsbetween 1,922 unique proteins and the risk of LTL and six major CVDs using the summary

404 data-based Mendelian randomization (SMR), each protein with index cis-acting variants 405 (cis-pQTL) obtained from the UK Biobank Pharma Proteomics Project (UKB-PPP). 406 Following the exclusion of associations failing the HEIDI test, and after conducting 407 sensitivity analysis with multi-SNPs-SMR and applying multiple testing corrections via 408 Bonferroni adjustment, the genetically predicted levels of 85 proteins were found to be 409 significantly associated with the risk of LTL and CVDs (Fig. 6, Supplementary Table 18). 410 Specifically, 12, 9, 26, 24, 2, 6, and 6 proteins were significantly associated with LTL, AF, 411 CAD, VTE, HF, PAD, and Stroke, respectively. Notably, SH2B3 emerged as significantly 412 associated with both LTL-CAD and LTL-VTE, also showing strong colocalization evidence in 413 HyPrColoc analysis, with rs10774625 pinpointed as a shared causal variant. The index SNP 414 rs10774625, located at the 12q24.12 locus (an intronic variant of the ATXN2 gene), was associated with eQTLs in whole blood ($P_{Whole, Blood} = 3.48 \times 10^{-4}$) and was also linked to pQTLs 415 in whole blood ($P_{Whole Blood} = 1.08 \times 10^{-3}$) for the SH2B adaptor protein 3 (SH2B3). SH2B3 416 417 acted as an adaptor protein, playing a crucial role in negatively regulating cytokine signaling 418 and cell proliferation. Prior research indicated that SH2B3 was associated with longevity, 419 with missense alleles within SH2B3 influencing life expectancy through predisposition to 420 cardiovascular events²⁶. Enhancing SH2B3 function has demonstrated therapeutic potential in 421 hypertension and other cardiovascular conditions.

422

423 Discussion

424 In this extensive genome-wide pleiotropy association study, we systematically elucidated the 425 shared genetic architecture beyond genome-wide genetic correlations between LTL and six 426 major CVDs, uncovering no causal relationships between them. Subsequent in-depth analyses 427 identified pleiotropic genetic variants and loci, pleiotropic genes, biological pathways, and 428 protein targets, all reinforcing the involvement of the DNA biosynthesis and telomere 429 maintenance in the shared genetic etiology of these traits. Overall, these findings offer novel 430 insights into the relationship and shared genetic mechanisms underlying LTL and six major 431 CVDs.

432

433 Consistent with prior robust epidemiological evidence, our findings reveal weak to moderate,

434 yet significant, negative genome-wide genetic correlations between LTL and six major CVDs, 435 except for LTL-AF. Beyond mere genetic correlations, our analysis uncovers a more extensive 436 degree of genetic overlap between LTL and CVDs using MiXeR and LAVA, involving a 437 broad mixture of both concordant and discordant effect sizes. Employing MiXeR, we 438 demonstrated that the polygenicity of LTL and CVDs presents fundamental distinctions 439 beyond SNP-based heritability. Briefly, LTL was substantially less polygenic than three CVD 440 phenotypes (CAD, HF, and Stroke), yet exhibited similar polygenicity to other CVD 441 phenotypes, including AF, VTE, and PAD. Despite notable differences in polygenicity, we 442 observed extensive genetic overlaps between LTL and all CVDs, supported by LAVA local 443 correlations. This pattern emerged in cases of weak or non-significant genome-wide genetic 444 correlations, such as between LTL and AF, and in strong genome-wide correlations, such as 445 between LTL and PAD. For example, despite the absence of genome-wide genetic 446 correlations, a pronounced fraction of the genetic risk underlying LTL overlaps with AF was 447 indicated using MiXeR. The findings correspond with the discovery of a similar number of 448 positively and negatively correlated genomic regions between LTL and AF by LAVA, 449 alongside further detecting much more shared pleiotropic loci below the genome-wide 450 significance threshold. Although the local genetic correlations encompassed genomic regions 451 averaging approximately 1 megabase (Mb) in width, this resolution required refinement to 452 minimize the impact of heterogeneous effects on estimation accuracy. For example, we noted 453 inconsistent effects across lead variants in the LTL and AF pleiotropic analysis. Specifically, 454 out of 47 top lead variants, 28 demonstrated the same effect direction for LTL and AF, 455 whereas the remaining 19 exhibited opposite effect directions. This indicates that pleiotropic 456 analysis at the level of single variants was necessary to offer further, more detailed insights 457 into the shared genetic underpinnings across complex traits. These findings indicate that 458 genetic overlap between LTL and CVDs was greatly underestimated due to the patterns of 459 mixed effect directions concealed by estimates of genome-wide genetic correlations.

460

461 The intricate relationship between LTL and six major CVDs may be further elucidated by 462 examining the vertical and horizontal pleiotropy mechanisms that underpin their shared 463 genetic basis. The causal relationships between LTL and six major CVDs were then

464 predominantly elucidated by the effects attributed to vertical pleiotropy. Using more recent 465 GWAS summary data, we discovered minimal evidence supporting the causal effects of LTL 466 on CVDs and vice versa using LCV and LHC-MR. This finding stood in stark contrast to 467 existing research that suggested such effects were present. Previous two-sample MR studies 468 have reported associations between genetic liability to LTL shortening and the increased risk 469 of CAD and Stroke, but results for the risk of HF have been inconsistent. Another study even 470 demonstrated that genetically predicted AF contributes to the shortening of LTL rather than 471 the reverse. Indeed, the majority of GWAS meta-analyses of CVDs have incorporated 472 samples from the UK Biobank, resulting in considerable sample overlap with GWAS studies 473 on LTL, which might contravene the basic principles of two-sample MR. In addition, the 474 interpretation of the MR estimate in this case was quite complicated by the fact that both LTL 475 and CVDs were time-varying outcomes with a late age of onset. Consequently, our study's 476 findings suggest that the association between LTL and CVDs may have been greatly 477 overestimated in prior research, potentially as a result of sample overlap, reverse causation, or 478 unmeasured heritable confounding factors, indicating that pleiotropic and common biological 479 pathways may be a better explanation for their association.

480

481 The horizontal pleiotropic analyses, encompassing different levels such as pleiotropic genetic 482 variants and loci, pleiotropic genes, biological pathways, and protein targets, revealed 483 significant genetic overlaps between LTL and CVDs from another perspective from another 484 perspective. At the SNP level, pleiotropic variants linking LTL and CVDs were broadly 485 distributed, with a notable emphasis on shared pleiotropic loci among certain trait pairs, 486 including 16q22.1 (TMED6), 8p21.3 (XPO7), 17p13.3 (SERPINF1), and 12q24.12 (ATXN2). 487 For example, the transmembrane emp24 domain-containing protein 6 precursor (TMED6), 488 highly and selectively expressed in pancreatic islets, was found to be associated with LTL and 489 all CVDs, which belonged to the EMP24_GP25L superfamily and played a crucial role in 490 protein trafficking and secretion. Knockdown of the *TMED6* gene in Min6 β -cells and INS1 491 cells led to a reduction in glucose-stimulated insulin secretion, suggesting that dysregulation of *TMED6* may play a critical role in the onset of type 2 diabetes^{27,28}. To date, there have been 492 493 no reports of an association between TMED6 and either LTL or CVDs, hinting at a potential

494 biological mechanism that may be mediated through CVD risk factors, particularly type 2 495 diabetes. Exportin-7 (XPO7) is a bidirectional transporter regulating the nuclear-cytoplasmic 496 shuttling of a wide array of substrates, yet its function remains relatively obscure.²⁹. Recent 497 research has identified XPO7 as a novel regulator of cellular senescence. The depletion of 498 XPO7 leads to decreased levels of TCF3 (transcription factor 3, also known as E2A) and impaired induction of the cyclin-dependent kinase inhibitor p21^{CIP1}, which was critical during 499 oncogene-induced senescence³⁰. The role and malfunction of the Serpin Family F Member 1 500 501 (SERPINF1), also known as the pigment epithelium-derived factor (PEDF) gene, in the aging 502 process has currently been a hot topic. Briefly, the reduction in *PEDF* expression levels, both 503 directly and indirectly, can prompt cellular senescence via the modulation of various signaling pathways^{31,32}. Studies have also demonstrated that *PEDF* possesses insulin-sensitizing effects 504 505 in the liver and adipose tissues and exhibits anti-inflammatory, anti-thrombogenic, and 506 vasculoprotective properties in vivo, offering protection against metabolic syndrome and 507 cardiovascular diseases^{33,34}. Overall, this study extends previous findings on shared genetic 508 architecture by offering a more comprehensive characterization of specific pleiotropic loci.

509

510 At the gene level, we employed two gene-mapping strategies to identify credible mapped 511 genes for all jointly associated pleiotropic loci. Seven genes, namely ALDH2, ACAD10, 512 TMEM116, SH2B3 (all located at 12q24.12), TMED6 (16q22.1), SERPINF1 (17p13.3), and 513 *XPO7* (8p21.3), have emerged as the most pleiotropic; they are thought to have important 514 regulatory functions, influencing over half of the trait pairs examined. For example, among 515 these genes, ALDH2 and ACAD10, located at the 12q24.12 locus, were associated with LTL 516 and all CVDs except AF. Aldehyde dehydrogenase 2 (ALDH2) is the gene with the highest 517 number of genetic polymorphisms in humans; it is involved in encoding a mitochondrial 518 enzyme critical for detoxifying reactive aldehydes. For example, the ALDH2 rs671 519 inactivating polymorphism, found in up to 8% of the global population and up to 50% of the 520 East Asian population, is associated with an elevated risk of several CVDs, such as CAD. 521 While numerous studies have connected aldehyde accumulation, due to alcohol consumption, 522 ischemia, or heightened oxidative stress, to elevated CVD risk, this accumulation alone does not fully account for their complex interactions^{35,36}. Moreover, previous studies indicated that 523

524 the ALDH2 enzyme might also exacerbate myocardial remodeling and contractile dysfunction 525 during aging, potentially via AMPK/Sirt1-mediated mitochondrial damage. Acyl-CoA 526 dehydrogenase family member 10 (ACAD10) gene encoded an enzyme involved in fatty acid beta-oxidation in mitochondria³⁷. ACAD10 is predominantly expressed in the human brain 527 528 and is believed to play a role in physiological functions within the central nervous system, 529 such as the regulation of cellular lipid synthesis. ACAD10 has previously been identified as 530 one of the putative causal genes for CAD, stroke, and hypertension, a common risk factor for CVDs³⁸. Collectively, these findings imply that ACAD10 has a significant role in regulating 531 532 lipid synthesis through distinct molecular and cellular pathways, potentially influencing the 533 development of CVDs. Further research is required to elucidate the precise mechanisms of 534 interaction between ACAD10 and both LTL or CVDs.

535

536 The 12q24.12 locus was a top hit region, which identified as pleiotropic for all correlated trait 537 pairs except for LTL-AF and exhibited strong evidence of colocalization between these trait 538 pairs. Besides, HyPrColoc further revealed robust colocalization evidence for this locus 539 between LTL and all CVDs, excluding AF and PAD, encompassing the shared causal SNP 540 (i.e., rs10774625). LAVA results supported these findings and showed consistent negative 541 local genetic correlations between LTL and all CVDs, except for AF, HF and PAD. The index 542 SNP rs10774625 polymorphism has been reported to be associated with a variety of CVDs, 543 notably CAD, alongside cardiometabolic markers such as blood pressure and blood lipids. 544 The index SNP rs10774625, located at the 12q24.12 locus (an intronic variant of the ATXN2 545 gene), was associated with eQTLs and pQTLs in whole blood for the SH2B adaptor protein 3 546 (SH2B3). The proteome-wide Mendelian Randomization study revealed that the genetically 547 predicted levels of SH2B3 protein were significantly associated with both LTL-CAD and 548 LTL-VTE. SH2B3 is a member of the adapter protein family and plays a critical role in 549 negatively regulating cytokine signaling and cell proliferation. It was originally described as a 550 regulator of hematopoietic and lymphocyte differentiation and was implicated in the 551 transduction and regulation of growth factors and inflammation-related cytokine 552 receptor-mediated signaling. SH2B3 missense variants may affect lifespan through cardiovascular disease³⁹. Specifically, SH2B3 can lead to increased production of IFNy, which 553

554 acts as a pro-inflammatory mediator to induce the polarization of macrophages into different 555 states. This process is crucial for mediating inflammatory regulation and fibrosis post-myocardial infarction⁴⁰. On the other hand, IFN γ is released and activated by CD4 T 556 557 helper cells—specifically Th1 cells—which are instrumental in coordinating immune cell 558 infiltration and inflammation. The above immune cells and inflammatory signals are pivotal in the progression of non-ischemic heart failure in patients⁴¹. Notably, increased 559 cardiomyocyte size and fibrosis are critical characteristics of cardiac hypertrophy and 560 remodeling, which ultimately lead to heart failure⁴². Further studies have demonstrated that 561 562 cardiac-specific SH2B3 overexpression exacerbates pressure overload, leading to cardiac 563 hypertrophy, fibrosis, and dysfunction by activating focal adhesion kinase, which 564 subsequently triggers the downstream phosphoinositide 3-kinase-AKT-target of Programmed 565 Death-1 (PD-1). Significant overexpression of the SH2B3 gene promotes the activation of the 566 Akt signaling pathway, which can promote cardiac hypertrophy and fibrosis and lead to the deterioration of cardiac function⁴³. Meanwhile, age-related telomere dysfunction is a core 567 driver of inflammation⁴⁴. Therefore, SH2B3 may become one of the most promising 568 569 therapeutic targets for CVDs. In contrast, TMEM116, a member of the TMEM family of 570 proteins that spans the plasma membrane of cells to facilitate intercellular communication, 571 demonstrates a different aspect of disease association. Multiple members of the TMEM 572 family may be up or down-regulated in tumor tissues, and some of them are used as cancer prognostic biomarkers⁴⁵. However, in studies of cardiovascular diseases, this protein has only 573 been found to be related to coronary atherosclerosis⁴⁶, and the specific mechanism is unclear 574 575 and requires further research.

576

At the pathway level, functional analyses of the pleiotropic loci between LTL and CVDs have implicated genes involved in the metabolic processes of nucleobase-containing compounds, including DNA biosynthesis and telomere maintenance. There is a close relationship between telomere maintenance, telomerase expression, and extension of cell lifespan. Telomeres undergo shortening during repeated cell divisions, and when their length diminishes to a critical point, the resultant genomic instability can lead to further genetic abnormalities that promote cell death or apoptosis, which is a hallmark of cellular senescence. Estrogen, stress

584 accumulation from oxidative damage, hypertension, etc., are believed to significantly impact 585 telomere homeostasis and contribute to the development of CVDs⁴⁷. This finding bolsters the 586 theory that progressive telomere shortening contributes to the pathogenesis of age-related 587 human diseases such as CVDs. Specifically, Minano et al. documented the presence of 588 vascular endothelial cells exhibiting age-related phenotypes within human atherosclerotic 589 lesions⁴⁸. Excessive vascular smooth muscle cells are stimulated to proliferate and migrate, 590 leading to the growth of atherosclerosis. Besides, telomerase activation and telomere 591 maintenance are critical in increasing the proliferation and growth of vascular smooth muscle 592 cells. Activation through the telomerase reverse transcriptase component (TERT) extends the 593 lifespan of cultured vascular smooth muscle cells. Conversely, telomerase inhibition can 594 extend the lifespan and reduce the proliferation of cultured vascular smooth muscle cells, thereby decreasing the risk of atherosclerosis⁴⁹. Therefore, these findings highlight the role of 595 596 telomeres in cardiovascular health, suggesting that methods to modulate the balance of 597 telomerase activity may be critical for developing effective interventions for related CVDs.

598

599 There were some limitations to the current study. Firstly, the main analysis focused solely on 600 individuals of European ancestry due to the scarcity of sufficiently powered GWAS involving 601 other ancestries. Nevertheless, we utilized GWAS summary data from East Asian ancestries 602 for replication, partially confirming the consistency of the genetic foundation identified in the 603 European sample. Future studies with a trans-ancestral approach are necessary to evaluate the 604 universality of these findings. Secondly, the analysis focused on common genetic variants that 605 account for only a small fraction of overall disease risk. The remaining variance was likely 606 attributable to many undetected SNPs, rare variants, or gene interactions. Therefore, they need 607 to be further studied to achieve a more complete understanding. Thirdly, although we 608 uncovered the potential shared genetic architecture, the mechanisms of shared biological 609 pathways still require further experimental validation. Finally, our analysis of GWAS 610 summary data encompassed six major CVDs, representing a significant portion of the genetic 611 risk architecture for these conditions, though not comprehensively. As GWAS datasets expand, 612 it will be crucial to undertake cross-trait analyses incorporating more varied datasets and 613 additional diseases to enhance our understanding.

614

615 **Conclusion**

In conclusion, we found extensive polygenic overlap between LTL and CVDs, with distinct patterns of genetic correlations and effect directions, uncovering no causal relationships. It was proved that LTL and six major CVDs share pleiotropic genetic variants, loci, genes, biological pathways, and protein targets, underscoring the role of DNA biosynthesis and telomere maintenance in their common genetic etiology. These findings elucidate the interconnected mechanisms between LTL and CVDs, potentially guiding targeted therapies and clinical practice.

622

623 Methods

624 Data Sources and Quality Control

625 Figure 1 outlines the workflow for our study. Due to the confounding effects of ancestral 626 differences in linkage disequilibrium (LD) structure and the scarcity of sufficiently large 627 multi-ancestry samples, we limited our main analysis to individuals of European ancestry. We 628 sourced genome-wide association study (GWAS) summary statistics from the most 629 comprehensive and recent publicly available datasets of European ancestry. Specifically, 630 GWAS summary statistics for leukocyte telomere length (LTL) were derived from a published 631 GWAS comprising 464,716 individuals of European ancestry from the UK Biobank⁷. LTL 632 was quantified as the ratio of telomere repeats copy number (T) to a single copy gene (S) in a 633 mixed leukocyte population, measured via a multiplex quantitative polymerase chain reaction 634 (qPCR) assay, and subsequently log-transformed to achieve an approximation to a normal 635 distribution. Our selection criteria for GWAS included studies with sample sizes exceeding 636 50,000 to ensure adequate statistical power. Accordingly, we included GWAS summary 637 statistics for six major cardiovascular diseases (CVDs): atrial fibrillation (AF)⁸, coronary artery disease (CAD)⁹, venous thromboembolism (VTE)¹⁰, heart failure (HF)¹¹, peripheral 638 artery disease (PAD)¹², and stroke¹³. AF GWAS summary statistics were sourced from a 639 640 genome-wide meta-analysis of six studies (The Nord-Trøndelag Health Study [HUNT], 641 deCODE, the Michigan Genomics Initiative [MGI], DiscovEHR, UK Biobank, and the Atrial 642 Fibrillation Genetics [AFGen] Consortium), encompassing 60,620 AF cases and 970,216 643 controls of European ancestry. For CAD, we utilized GWAS summary statistics from a

644 genome-wide meta-analysis by the CARDIoGRAMplusC4D Consortium and the UK 645 Biobank, which included 181,522 cases and 984,168 controls. VTE GWAS summary statistics 646 were extracted from a meta-analysis of 81,190 cases and 1,419,671 controls of European 647 ancestry across 7 cohorts (the Copenhagen Hospital Biobank Cardiovascular Disease Cohort 648 [CHB-CVDC], Danish Blood Donor Study [DBDS], deCODE, Intermountain Healthcare, UK 649 Biobank, FinnGen, and Million Veterans Program [MVP] Consortium). GWAS summary 650 statistics for HF came from the Heart Failure Molecular Epidemiology for Therapeutic 651 Targets (HERMES) Consortium, including 47,309 cases and 930,014 controls. GWAS 652 summary statistics for PAD were derived from a genome-wide meta-analysis of 11 653 independent GWASs, totaling 12,086 cases and 499,548 controls. Lastly, GWAS summary 654 statistics for Stroke were obtained from the GIGASTROKE consortium, which comprised 655 73,652 cases and 1,234,808 controls of European ancestry. Detailed information about these 656 GWAS summary statistics and their original publication sources is available in Supplementary 657 Table 1.

658

659 Prior to further analysis, stringent quality control measures were applied to the GWAS 660 summary statistics, encompassing several key steps: (i) alignment with the hg19 genome 661 build, referencing the 1000 Genomes Project Phase 3 Europeans; (ii) restriction of the 662 analysis to autosomal chromosomes; (iii) removal of single nucleotide polymorphisms (SNPs) 663 lacking a rsID or presenting duplicated rsIDs; and (iv) exclusion of rare or low-frequency 664 variants, defined by a minor allele frequency (MAF) less than 1%. To ensure robust and 665 interpretable comparisons between LTL and CVDs, we standardized the summary statistics to 666 include only SNPs present across all analyzed phenotypes, resulting in a cohesive dataset of 667 6,923,146 SNPs. Additionally, in subsequent analyses, we implemented further data 668 processing techniques tailored to the specific requirements of various statistical tools.

669

670 Genetic overlap

To explore the shared genetic foundations between LTL and six major CVDs, we evaluated

- 672 genetic overlap across genome-wide, polygenic, and local levels.
- 673

674 Genome-wide genetic correlation analysis between LTL and CVDs

675 At the genome-wide level, we analyzed SNP-level heritability for each trait and the genetic 676 correlations (r_{e}) between LTL and six major CVDs using cross-trait linkage disequilibrium (LD) score regression (LDSC)^{50,51}. LDSC facilitates the estimation of the average genetic 677 678 effect sharing across the entire genome between two traits, leveraging GWAS summary 679 statistics. This includes the contribution of SNPs below the threshold of genome-wide 680 significance and accounts for potential confounding factors such as polygenicity, sample overlap, and population stratification. First, SNP-based heritability $(h^2_{SNP},$ representing the 681 682 fraction of phenotypic variation explained by common genetic variations included in the 683 study) for LTL and six major CVDs was estimated using univariate LDSC. This analysis 684 utilized pre-computed LD scores from the European reference panel in the 1000 Genomes 685 Project Phase 3, excluding SNPs that did not overlap with the reference panel. Notably, the 686 major histocompatibility complex (MHC) region (chr 6: 25-35 Mb), known for its intricate 687 LD structure, was omitted from the main analysis. Second, bivariate LDSC analysis estimated 688 the genetic correlations between LTL and the six major CVDs. This method utilizes a 689 weighted linear model, where it regresses the product of Z-statistics from two traits against 690 the LD score across all genetic variants genome-wide. Genetic correlations with P-values 691 below the Bonferroni-adjusted threshold (P = 0.05 / number of trait pairs = 0.05 / 6 = 692 8.33×10^{-3}) were deemed statistically significant.

693

694 To elucidate the biological underpinnings of the shared genetic predisposition to LTL and six 695 major CVDs, we employed stratified LDSC applied to specifically expressed genes 696 (LDSC-SEG) to identify relevant tissue and cell types. This analysis incorporated tissue and 697 cell type-specific expression data from the Genotype-Tissue Expression (GTEx) project and 698 the Franke lab, covering 53 tissues and 152 cell types. Additionally, we utilized 699 chromatin-based annotations associated with six epigenetic marks (DNase hypersensitivity, 700 H3K27ac, H3K4me1, H3K4me3, H3K9ac, and H3K36me3) for validation purposes. These 701 annotations included 93 labels from the Encyclopedia of DNA Elements (ENCODE) project 702 and 396 labels from the Roadmap Epigenomics database. For the identified relevant tissues or 703 cell types, we adjusted the *P*-values for the significance of the coefficients using the False

704 Discovery Rate (FDR) method. An FDR threshold of < 0.05 was established as the criterion

705 for statistical significance.

706

707 Polygenic overlap analysis between LTL and CVDs

708 To augment the genome-wide genetic correlation analysis, we engaged the causal mixture 709 modeling approach (MiXeR) to quantify the polygenic overlap between LTL and six major CVDs, independent of genetic correlation directions. MiXeR estimates the quantity of shared 710 711 and phenotype-specific "causal" variants that exert non-zero additive genetic effects, 712 accounting for 90% of SNP-heritability in each trait⁵². This 90% SNP-heritability threshold 713 minimizes the influence of variants with negligible effects. Importantly, MiXeR's capacity to 714 evaluate polygenic overlap without regard to the directional effects of variants offers a 715 nuanced view of local genetic associations that might be obscured in traditional genome-wide 716 genetic correlation estimations due to opposing variant effects. Initially, univariate MiXeR 717 analyses estimated the "causal" variant count for LTL and six major CVDs, assessing both 718 polygenicity and the average magnitude of additive genetic effects among these variants. The 719 LD structure was determined using the genotype reference panel from the 1000 Genomes 720 Project Phase 3. The MHC region (chr 6: 25-35 Mb), known for its intricate LD structure, was 721 excluded from the main analysis. Subsequently, bivariate MiXeR analysis quantified the 722 polygenic overlap between LTL and the six CVDs. This analysis delineated the additive 723 genetic effects across four categories: (i) SNPs with zero effect on both traits, (ii) 724 trait-specific SNPs with non-zero effects on the first trait, (iii) trait-specific SNPs with 725 non-zero effects on the second trait, and (iv) SNPs affecting both traits. The Dice coefficient 726 (DC), representing the proportion of shared SNPs between two traits relative to the total 727 number of SNPs associated with either trait, was used to estimate polygenic overlap. 728 Additionally, MiXeR calculated the overall genetic correlations (r_g) , the correlation of effect 729 sizes within the shared genetic component ($r_{e}s$), and the fraction of variants with concordant 730 effects in the shared component. The model's predictive accuracy was evaluated through 731 comparison of the modeled versus actual data, utilizing conditional quantile-quantile (Q-Q) 732 plots, log-likelihood plots, and the Akaike information criterion (AIC). Positive AIC 733 differences are interpreted as evidence that the best-fitting MiXeR estimates are

distinguishable from the reference model. A negative AIC value indicates that the MiXeR

735 model fails to distinguish effectively between maximal and minimal overlap scenarios.

736

737 Local genetic correlation between LTL and CVDs

738 To investigate whether there are any genomic loci with pronounced genetic correlations 739 despite negligible genome-wide r_{g} , we utilized the Local Analysis of [co]Variant Annotation 740 (LAVA) method to estimate the localized genetic correlation between LTL and six major 741 CVDs. LAVA, grounded in a fixed-effects statistical model, enables the estimation of local 742 SNP heritability (loc- h_{SNP}^2) and genetic correlations (loc- $r_c s$) across 2,495 semi-independent 743 genetic regions of approximately equal size (~1 Mb). This method is adept at identifying loci 744 with mixed effect directions, offering a nuanced measure of genome-wide genetic overlap, 745 albeit influenced by the statistical power of the underlying GWAS data. For this analysis, we 746 adopted the genomic regions defined by Werme et al. as autosomal LD blocks, characterized 747 by minimal inter-LD block linkage with an average size of 1 million bases, each containing at 748 least 2500 variants. The LD reference panel from the 1000 Genomes Project Phase 3 for 749 European samples was employed, and consistent with LDSC and MiXeR analyses, the MHC 750 region (chr 6: 25-35 Mb) was excluded. Identifying meaningful loc- r_{es} requires a significant local genetic signal; thus, a stringent P-value threshold ($P < 1 \times 10^{-4}$) was applied to filter out 751 752 non-significant loci. Subsequent bivariate testing on selected loci and traits with notable 753 univariate genetic signals was conducted. For these loci, P-values for $loc-r_{oS}$ were adjusted 754 using the Benjamini-Hochberg FDR method, with an FDR < 0.05 establishing statistical 755 significance. LAVA incorporated an estimate of sample overlap (genetic covariance intercept) 756 from bivariate LDSC analyses to account for potential sample overlap effects.

757

In cases where shared risk loci were identified across multiple phenotypes, the Hypothesis Prioritisation for multi-trait Colocalization (HyPrColoc) method was employed to assess whether association signals across more than a pair of traits were colocalized. HyPrColoc, an efficient deterministic Bayesian clustering algorithm, leverages GWAS summary statistics to identify clusters of colocalized traits and potential causal variants within a genomic locus, providing a posterior probability (PP) of colocalization for each cluster. Loci with a PP > 0.7

vere deemed colocalized, enhancing our understanding of shared genetic architectures across

765 traits.

766

767 Pleiotropy insights to dissect genetic overlap

768 Causal inference between LTL and CVDs

769 To elucidate the potential causal relationships underlying the genetic correlations observed 770 between LTL and six major CVDs, we employed latent causal variable (LCV) analysis. This 771 method posits that the genetic correlation between two traits operates through a latent factor, 772 allowing for the distinction between genetic causality (vertical pleiotropy) and both correlated and uncorrelated horizontal pleiotropy⁵³. It achieves this by estimating the genetic causality 773 774 proportion (GCP) across all genetic variants, where GCP quantifies the share of each trait's 775 heritability explained by a mutual latent factor. It is essential to emphasize that GCP does not 776 indicate the magnitude of causal effects but only implies a causal relationship between traits. 777 This method offers insights to evaluate whether the impact of one trait on the second exceeds 778 the evidence in the reverse direction. The sign of genetic correlation can be employed to infer 779 the consequence of the partial genetic causality of one trait on another. A GCP greater than 780 zero suggests a partial genetic causal relationship from trait 1 to trait 2 and vice versa, with 781 values closer to |GCP| = 1 indicating stronger evidence of vertical pleiotropy. Conversely, a 782 GCP of zero implies horizontal pleiotropy. We considered an absolute GCP estimate (|GCP|) 783 greater than 0.60 as indicative of substantial genetic causality, applying a Bonferroni-corrected significance threshold of $P < 8.33 \times 10^{-3}$ to account for multiple 784 785 comparisons across trait pairs. The LCV analysis, while robust, assumes a singular, 786 unidirectional latent variable driving the genetic correlation, a premise potentially confounded 787 by bidirectional causal effects or multiple latent factors.

788

Addressing the limitations inherent to LCV, we also conducted an analysis using Latent Heritable Confounder Mendelian Randomization (LHC-MR)⁵⁴. This advanced Mendelian randomization approach leverages genome-wide variants to explore bi-directional causal associations between complex traits, thus enhancing the capacity to discern bi-directional genetic effects, direct heritabilities, and confounder effects, even amidst sample overlap. By

modeling an unobserved heritable confounder affecting both exposure and outcome traits, LHC-MR assures the critical assumption of exchangeability⁵⁵. Its comprehensive modeling of potential SNP effects-direct, indirect, or null-on the traits offers more accurate causal effect estimates compared to traditional MR methods, such as MR Egger, weighted median, inverse variance weighted (IVW), simple mode, and weighted mode⁵⁶⁻⁵⁸. For statistical significance, we adjusted for multiple testing with a threshold of $P < 4.17 \times 10^{-3}$, considering both the number of trait pairs and the number of tests conducted.

801

802 Pairwise Pleiotropic analysis between LTL and CVDs

803 To delve into the role of horizontal pleiotropy between LTL and six major CVDs, we utilized 804 the Pleiotropic Analysis under the Composite Null Hypothesis (PLACO) method to conduct a 805 comprehensive genome-wide identification of pleiotropic SNPs that concurrently influence 806 the risk of both traits simultaneously. PLACO operates on the composite null hypothesis that 807 asserts a genetic variant is either associated with just one or neither trait, thereby distinguishing between pleiotropic effects and singular trait associations⁵⁹. The method 808 809 evaluates this hypothesis by examining the product of the Z statistics derived from the GWAS 810 summary statistics of both traits, formulating a null distribution of the test statistic as a 811 mixture distribution. This allows for the acknowledgment of SNPs that may be linked to only 812 one or none of the phenotypes under study. The threshold for identifying pleiotropic SNPs with significant evidence of genome-wide pleiotropy was set at $P_{PLACO} < 5 \times 10^{-8}$. Additionally, 813 814 to adjust for possible sample overlap, we de-correlated the Z-scores using a correlation matrix 815 directly estimated from the GWAS summary statistics, ensuring a more accurate interpretation 816 of pleiotropic effects.

817

818 Characterization of pleiotropic loci and functional annotation

The Functional Mapping and Annotation of Genome-Wide Association Studies (FUMA) platform was employed to identify independent genomic loci and conduct functional annotation for pleiotropic SNPs revealed by PLACO analysis⁵⁹. FUMA, leveraging data from 18 biological databases and analytical tools, annotates GWAS findings to highlight probable causal genes through positional and eQTL mapping ⁶⁰. The 1000 Genomes Project Phase 3

824 European-based LD reference panels were utilized for LD structure correction. Initially, 825 FUMA distinguishes independent significant SNPs (meeting genome-wide significance at P < 5×10^{-8} and $r^2 < 0.6$), further defining a subset as lead SNPs based on mutual independence (r^2 826 827 < 0.1). LD blocks within 500 kb of lead SNPs are merged to delineate distinct genomic loci, 828 with the SNP exhibiting the lowest *P*-value in each locus designated as the top lead SNP. The 829 analysis then assesses directional effects between LTL and six major CVDs by comparing Z-scores of these top lead SNPs. SNPs achieving genome-wide significance ($P < 5 \times 10^8$) in 830 individual GWAS for each trait were annotated using FUMA for comparative analysis. The 831 832 identified pleiotropic loci were considered novel if they did not coincide with the loci 833 previously reported in the original GWAS for LTL or any of the six major CVDs. In other 834 words, to be deemed 'novel,' a locus identified through FUMA should not have exhibited 835 statistical significance in the single trait GWAS.

836

837 To elucidate the biological underpinnings of the observed statistical associations, lead SNPs were annotated using Annotate Variation (ANNOVAR)⁶¹ for their proximity to genes and 838 839 potential impact on gene function. The Combined Annotation-Dependent Depletion (CADD) score⁶², which aggregates insights from 67 annotation resources, was used to assess the 840 841 deleteriousness of variants. Variants with CADD scores greater than 12.37 were deemed 842 likely to exert deleterious effects. Furthermore, the RegulomeDB score provided a categorical 843 assessment of an SNP's regulatory potential based on expression quantitative trait loci (eQTL) 844 and chromatin marks, ranging from 1 (strong evidence of regulatory functionality) to 7 $(minimal evidence)^{63}$. The highest regulatory potential is indicated by a score of 1a, while a 845 846 score of 7 suggests the least regulatory significance. Chromatin states, determined by 847 ChromHMM using data from 127 epigenomes and five chromatin marks, revealed the 848 genomic regions' accessibility, categorized into 15 states. For the identification of putative 849 causal genes, SNPs were mapped using two approaches: positional mapping within a 10-kb 850 window around the SNP and eQTL mapping.

851

852 Colocalization analysis

853 For pleiotropic loci identified and annotated by FUMA, we conducted a colocalization

854 analysis using COLOC to pinpoint potential shared causal variants across pairwise traits 855 within each locus. COLOC evaluates five mutually exclusive hypotheses for each pair of traits at a locus⁶⁴: H0 posits no association with either trait; H1 and H2 suggest an association 856 857 with only one of the traits; H3 indicates that both traits are associated due to different causal 858 variants; and H4 implies a shared association for both traits stemming from the same causal 859 variant. The analysis was performed using default COLOC prior probabilities: p1 and p2, each set at 1×10^{-4} for an SNP's association with the first and second trait, respectively, and 860 p12 at 1×10^{-5} for an SNP associated with both traits. A Posterior Probability for Hypothesis 4 861 862 (PP.H4) greater than 0.7 was considered strong evidence for colocalization, suggesting the 863 presence of shared causal variants at the locus. The SNP exhibiting the highest PP.H4 was 864 identified as a candidate causal variant.

865

866 Gene level analyses

867 Building on the insights from PLACO, we delved into the shared biological processes and 868 pathways involving the identified pleiotropic loci. Through gene-level analysis using 869 Multi-marker Analysis of GenoMic Annotation (MAGMA), we assessed genes within or 870 intersecting the pleiotropic loci, integrating data from both PLACO and single-trait GWAS. 871 Unlike permutation-based approaches, MAGMA employs a multiple regression model that 872 incorporates principal component analysis to evaluate gene associations. This model 873 calculates a p-value for each gene, aggregating the impact of all SNPs linked to that gene 874 while considering gene size, SNP count per gene, and linkage disequilibrium (LD) among the 875 markers. SNPs were attributed to genes based on their location within the gene body or within 876 a 10 kb range upstream or downstream. The LD calculations leveraged the 1000 Genomes 877 Project Phase 3 European population as the reference panel, with SNP locations determined 878 using the human genome Build 37 (GRCh37/hg19) and focusing on 17,636 autosomal 879 protein-coding genes. A gene was deemed significant if its p-value was below 0.05 after 880 applying a Bonferroni correction for the total number of protein-coding genes and the six trait 881 pairs analyzed ($P = 0.05 / 17,636 / 6 = 4.73 \times 10^{-7}$). Due to complex LD patterns, the MHC 882 region (chr6: 25-35 Mb) was excluded from MAGMA's gene-based analysis.

884 To overcome the limitations of MAGMA, which assigns SNPs to their nearest genes based on 885 arbitrary genomic windows potentially missing functional gene associations due to long-range 886 regulatory effects, we employed eQTL-informed MAGMA (e-MAGMA) for a more nuanced 887 investigation of tissue-specific gene involvement based on PLACO results. e-MAGMA 888 retains the statistical framework of MAGMA, using a multiple linear principal component 889 regression model, but enhances gene-based association analysis by incorporating 890 tissue-specific cis-eQTL information for SNP assignment to genes, which yields more 891 biologically relevant and interpretable findings. For our analysis, we utilized eQTL data from 892 47 tissues provided by the GTEx v8 reference panel, as available on the e-MAGMA website. 893 Guided by the principle that analyses focused on disease-relevant tissues yield more pertinent 894 insights, we selected ten relevant tissues for our study. These included three artery tissues, 895 two adipose tissues, two heart tissues, and three additional tissues (whole blood, liver, and 896 EBV-transformed lymphocytes), chosen based on their significant enrichment in the 897 LDSC-SEG analysis. The LD reference data for our analysis came from the 1000 Genomes 898 Phase 3 European panel. We calculated tissue-specific p-values for each gene across the 899 selected tissues, with significance determined post-Bonferroni correction for the number of 900 tissue-specific protein-coding genes and trait pairs examined. For instance, the significance threshold for adipose subcutaneous tissue was set at $P = 0.05 / 9.613 / 6 = 8.67 \times 10^{-7}$. Similar 901 902 to MAGMA, e-MAGMA analysis results within the MHC region (chr6: 25-35 Mb) were 903 excluded to avoid confounding due to complex LD patterns. Additionally, we conducted a 904 transcriptome-wide association study (TWAS) based on single-trait GWAS results using the 905 functional summary-based imputation software, FUSION, applying tissue-specific Bonferroni 906 corrections to determine significance. The FUSION approach integrates GWAS summary 907 statistics with pre-computed gene expression weights, referencing the same tissues analyzed 908 in the e-MAGMA study from the GTEx v8 dataset. This integration takes into account the LD 909 structures to identify significant relationships between gene expression levels and specific 910 traits.

911

912 Pathway level analyses

913 To investigate the genetic pathways underlying the comorbidity of LTL and six major CVDs,

914 we utilized MAGMA for gene-set analysis. This analysis employs a competitive approach, 915 where test statistics for all genes within a gene set, such as a biological pathway, are 916 aggregated to derive a joint association statistic. Gene sets were sourced from the Gene 917 Ontology biological processes (GO BP) via the Molecular Signatures Database (MsigDB), 918 with gene definitions and association signals derived from MAGMA gene-based analysis. We 919 adjusted for multiple testing using a Bonferroni correction, setting the threshold at P = 0.05 / $7.744 / 6 = 1.08 \times 10^{-6}$. We then conducted functional enrichment analysis on the genes 920 921 overlapping across more than one trait pair, which were significantly identified by both 922 MAGMA and e-MAGMA analyses. For this purpose, the ToppGene Functional Annotation 923 tool (ToppFun) was employed to identify significantly represented biological processes and 924 enriched signaling pathways, considering the entire genome as the background. ToppFun 925 performs Functional Enrichment Analysis (FEA) on the specified gene list, leveraging a broad 926 spectrum of data sources, including transcriptomics, proteomics, regulomics, ontologies, 927 phenotypes, pharmacogenomics, and bibliographic data. The list of candidate genes was 928 submitted to the ToppFun tool within the ToppGene Suite, with an FDR < 0.05 established as 929 the threshold for statistical significance.

930

931 Proteome-wide Mendelian Randomization study analysis

932 To explore potential common causal factors at the proteomic level, we utilized Summary 933 data-based Mendelian Randomization (SMR) to examine associations between protein 934 abundance and disease phenotype. This analysis leveraged index cis-acting variants 935 (cis-pQTLs) identified in the UK Biobank Pharma Proteomics Project (UKB-PPP), which 936 includes plasma samples from 34,557 European individuals with the measurement of 2,940 937 plasma proteins using the Olink Explore platform. Cis-pQTLs were defined as SNPs located 938 within a 1Mb radius from the transcription start site (TSS) of the gene encoding the protein. Only index cis-pQTLs associated with plasma protein levels at a genome-wide significance 939 threshold ($P < 5 \times 10^{-8}$) were considered for inclusion in the SMR analysis. Summary 940 941 data-based Mendelian Randomization (SMR) is designed to prioritize genes for which 942 expression levels are potentially causally linked to an outcome trait, utilizing summary 943 statistics within a Mendelian Randomization framework. To differentiate between pleiotropy

944 and linkage (where protein abundance and a phenotype manifestation could be influenced by 945 two separate causal variants in strong linkage disequilibrium with one another), the 946 Heterogeneity in Dependent Instrument (HEIDI) test was employed. A HEIDI test p-value 947 below 0.01 signifies the presence of two distinct genetic variants in high linkage 948 disequilibrium, explaining the observed associations. Additionally, to address potential biases 949 from analyzing single SNPs, a multi-SNP approach (multi-SNPs-SMR) was utilized as a 950 sensitivity analysis, enhancing the reliability of the statistical evidence. A p-value less than 951 0.05 in the multi-SNPs-SMR analysis was deemed significant. Furthermore, HyPrColoc 952 analysis was employed to ascertain whether the associations identified between proteins and 953 various diseases stemmed from the same causal variant or were due to linkage disequilibrium. 954 A posterior probability of a shared causal variant (PP.H4) greater than 0.7 signifies strong 955 evidence of colocalization between proteins and multiple diseases.

956

957 **Reporting summary**

958 Further information on research design is available in the Nature Portfolio Reporting

959 Summary linked to this article.

960

961 Data availability

962 The study used only openly available GWAS summary statistics on leukocyte telomere length 963 and six major cardiovascular diseases that have originally been conducted using human data. 964 GWAS LTL summary statistics on are available at 965 https://figshare.com/s/caa99dc0f76d62990195. GWAS summary statistics on AF, HF, and 966 Stroke are available at the GWAS Catalog (GCST90104539, GCST009541, and 967 GCST90104539). GWAS summary statistics on CAD and PAD are publicly available for 968 download at the Cardiovascular Disease Knowledge Portal (CVDKP) website: 969 https://cvd.hugeamp.org/datasets.html. GWAS summary statistics on VTE are obtained from 970 the deCODE genetics website: https://www.decode.com/summarydata/. Blood-based 971 from UKB-PPP obtained from https:// cis-pQTL are 972 www.synapse.org/#!Synapse:syn51365303, respectively.

973

974 Code availability:

- 975 All software used to conduct the analyses in this paper are freely available online. Software
- 976 (version, where applicable) and sources are listed below: LDSC (v1.0.1;
- 977 https://github.com/bulik/ldsc), MiXeR (v1.3; https://github.com/precimed/mixer), LAVA
- 978 (v0.1.0; https://github.com/josefin-werme/LAVA), LCV (https://github.com/lukejoconnor/
- 979 LCV); LHC-MR (v0.0.0.9000; https://github.com/LizaDarrous/lhcMR), PLACO (v0.1.1;
- 980 https://github.com/RayDebashree/PLACO), FUMA (v1.5.4; http://fuma.ctglab.nl/),
- 981 HyPrColoc(v1.0; https://github.com/jrs95/hyprcoloc), MAGMA (v.1.08; https://ctg.cncr.nl/
- 982 software/magma), e-MAGMA (https://github.com/eskederks/eMAGMA-tutorial), TWAS
- 983 (http://gusevlab.org/projects/fusion/), SMR (v1.31; https://yanglab.westlake.edu.cn/
- software/smr/), COLOC (v5.2.1; https://github.com/chr1swallace/coloc), and R (v.4.1.3;
- 985 https://www.r-project.org/).
- 986

987 Acknowledgements

988 This study was supported by the Natural Science Foundation of China Excellent Young 989 Scientists Fund (Overseas) (Grant no. K241141101), Guangdong Basic and Applied Basic 990 Research Foundation for Distinguished Young Scholars (Grant no. 24050000763), Shenzhen 991 Pengcheng Peacock Plan, Shenzhen Basic Research General Projects of Shenzhen Science and 992 Technology Innovation Commission (Grant no. JCYJ20230807093514029) (To Y.F.), National 993 Natural Science Foundation (Grant no. 82170339 and 82270241), NSFC Incubation Project of 994 Guangdong Provincial People's Hospital (Grant no. KY0120220021), Natural Science 995 Foundation of Guangdong Province (Grant no. 2023B1515020082) (To L.J.), National Natural 996 Science Foundation of China (Grant no. 82260073); Tianshan Talent Cultivation Program 997 Project of Xinjiang Uygur Autonomous Region (Grant no. 2022TSYCLJ0028) (To Y.Y.), and 998 Center for Computational Science and Engineering at Southern University of Science and 999 Technology. The funder had no role in the design, implementation, analysis, interpretation of 1000 the data, approval of the manuscript, and decision to submit the manuscript for publication.

1001

1002 Author contributions

1003 J.Q., Y. F., Y.Y., L.J., and S.P. conceptualized and supervised this project and wrote the

- 1004 manuscript. J.Q., Q.W., and Y.Z. performed the main analyses and wrote the manuscript. J.Q.,
- 1005 M.C., L.C., and F.L. performed the statistical analysis and assisted with interpreting the
- 1006 results. K.Y., L.Z., N.T., P.H., and A.J. provided expertise in cardiovascular biology and
- 1007 GWAS summary statistics. All authors discussed the results and commented on the paper.
- 1008

1009 Competing interests

1010 All authors declare no competing interests.

1011 **References**

- Blasco, M. A. Telomeres and human disease: ageing, cancer and beyond. *Nat Rev Genet* 6, 611-622, doi:10.1038/nrg1656 (2005).
- van der Harst, P. *et al.* Telomere length of circulating leukocytes is decreased in
 patients with chronic heart failure. *J Am Coll Cardiol* 49, 1459-1464,
 doi:10.1016/j.jacc.2007.01.027 (2007).
- 1017 3 Zheng, Y. *et al.* Association between leucocyte telomere length and the risk of atrial
 1018 fibrillation: An updated systematic review and meta-analysis. *Ageing Res Rev* 81,
 1019 101707, doi:10.1016/j.arr.2022.101707 (2022).
- Haycock, P. C. *et al.* Leucocyte telomere length and risk of cardiovascular disease:
 systematic review and meta-analysis. *Bmj* 349, g4227, doi:10.1136/bmj.g4227
 (2014).
- Njajou, O. T. *et al.* Telomere length is paternally inherited and is associated with
 parental lifespan. *Proc Natl Acad Sci U S A* 104, 12135-12139,
 doi:10.1073/pnas.0702703104 (2007).
- Broer, L. *et al.* Meta-analysis of telomere length in 19,713 subjects reveals high
 heritability, stronger maternal inheritance and a paternal age effect. *Eur J Hum Genet*21, 1163-1168, doi:10.1038/ejhg.2012.303 (2013).
- 1029 7 Codd, V. *et al.* Polygenic basis and biomedical consequences of telomere length
 1030 variation. *Nature genetics* 53, 1425-1433, doi:10.1038/s41588-021-00944-6 (2021).
- Nielsen, J. B. *et al.* Biobank-driven genomic discovery yields new insight into atrial
 fibrillation biology. *Nature genetics* 50, 1234-1239, doi:10.1038/s41588-018-0171-3
 (2018).
- Aragam, K. G. *et al.* Discovery and systematic characterization of risk variants and
 genes for coronary artery disease in over a million participants. *Nature genetics* 54,
 1803-1815, doi:10.1038/s41588-022-01233-6 (2022).
- 1037 10 Ghouse, J. *et al.* Genome-wide meta-analysis identifies 93 risk loci and enables risk
 prediction equivalent to monogenic forms of venous thromboembolism. *Nature* genetics 55, 399-409, doi:10.1038/s41588-022-01286-7 (2023).
- 1040 11 Shah, S. *et al.* Genome-wide association and Mendelian randomisation analysis

- 1042 163, doi:10.1038/s41467-019-13690-5 (2020).
- 1043 12 van Zuydam, N. R. *et al.* Genome-Wide Association Study of Peripheral Artery
 1044 Disease. *Circ Genom Precis Med* 14, e002862, doi:10.1161/circgen.119.002862
 1045 (2021).
- 13 Mishra, A. *et al.* Stroke genetics informs drug discovery and risk prediction across
 ancestries. *Nature* 611, 115-123, doi:10.1038/s41586-022-05165-3 (2022).
- 1048 14 Haycock, P. C. *et al.* Association Between Telomere Length and Risk of Cancer and
 1049 Non-Neoplastic Diseases: A Mendelian Randomization Study. *JAMA Oncol* 3,
 1050 636-651, doi:10.1001/jamaoncol.2016.5945 (2017).
- 1051 15 Deng, Y. *et al.* Telomere length and the risk of cardiovascular diseases: A Mendelian
 1052 randomization study. *Front Cardiovasc Med* 9, 1012615,
 1053 doi:10.3389/fcvm.2022.1012615 (2022).
- 1054 16 Sha, Z. *et al.* Causal relationship between atrial fibrillation and leukocyte telomere
 1055 length: A two sample, bidirectional Mendelian randomization study. *Front*1056 *Cardiovasc Med* 10, 1093255, doi:10.3389/fcvm.2023.1093255 (2023).
- 1057 17 (!!! INVALID CITATION !!!).
- 1058 18 Gong, W. *et al.* Role of the Gut-Brain Axis in the Shared Genetic Etiology Between
 1059 Gastrointestinal Tract Diseases and Psychiatric Disorders: A Genome-Wide
 1060 Pleiotropic Analysis. *JAMA Psychiatry* 80, 360-370,
 1061 doi:10.1001/jamapsychiatry.2022.4974 (2023).
- 19 Pisanu, C. *et al.* Dissecting the genetic overlap between severe mental disorders and
 markers of cellular aging: Identification of pleiotropic genes and druggable targets.
 Neuropsychopharmacology, doi:10.1038/s41386-024-01822-5 (2024).
- 1065 20 Levy, D. *et al.* Genome-wide association study of blood pressure and hypertension.
 1066 *Nature genetics* 41, 677-687, doi:10.1038/ng.384 (2009).
- Soranzo, N. *et al.* A genome-wide meta-analysis identifies 22 loci associated with
 eight hematological parameters in the HaemGen consortium. *Nature genetics* 41,
 1182-1190, doi:10.1038/ng.467 (2009).
- 1070 22 Chen, X., Ma, J., Wang, Z. W. & Wang, Z. The E3 ubiquitin ligases regulate

¹⁰⁴¹ provide insights into the pathogenesis of heart failure. *Nature communications* 11,

- 1071 inflammation in cardiovascular diseases. Semin Cell Dev Biol 154, 167-174,
- 1072 doi:10.1016/j.semcdb.2023.02.008 (2024).
- 1073 23 Choi, J. & Baek, K. H. Cellular functions of stem cell factors mediated by the
 1074 ubiquitin-proteasome system. *Cell Mol Life Sci* 75, 1947-1957,
 1075 doi:10.1007/s00018-018-2770-7 (2018).
- 1076 24 Brænne, I. *et al.* Prediction of Causal Candidate Genes in Coronary Artery Disease
 1077 Loci. *Arterioscler Thromb Vasc Biol* 35, 2207-2217, doi:10.1161/atvbaha.115.306108
 1078 (2015).
- He, M. *et al.* Identification and characterization of new long chain acyl-CoA
 dehydrogenases. *Mol Genet Metab* 102, 418-429, doi:10.1016/j.ymgme.2010.12.005
 (2011).
- Joshi, P. K. *et al.* Genome-wide meta-analysis associates HLA-DQA1/DRB1 and LPA
 and lifestyle factors with human longevity. *Nature communications* 8, 910,
 doi:10.1038/s41467-017-00934-5 (2017).
- Wang, X. *et al.* Transmembrane emp24 protein transport domain 6 is selectively
 expressed in pancreatic islets and implicated in insulin secretion and diabetes. *Pancreas* 41, 10-14, doi:10.1097/MPA.0b013e318223c7e4 (2012).
- 1088 28 Fadista, J. *et al.* Global genomic and transcriptomic analysis of human pancreatic
 1089 islets reveals novel genes influencing glucose metabolism. *Proc Natl Acad Sci U S A*
- **1090 111**, 13924-13929, doi:10.1073/pnas.1402665111 (2014).
- Aksu, M. *et al.* Xpo7 is a broad-spectrum exportin and a nuclear import receptor. J *Cell Biol* 217, 2329-2340, doi:10.1083/jcb.201712013 (2018).
- 1093 30 Innes, A. J. *et al.* XPO7 is a tumor suppressor regulating p21(CIP1)-dependent
 1094 senescence. *Genes Dev* 35, 379-391, doi:10.1101/gad.343269.120 (2021).
- Borg, M. L. *et al.* Pigment epithelium–derived factor regulates lipid metabolism via
 adipose triglyceride lipase. *Diabetes* 60, 1458-1466 (2011).
- Yamagishi, S.-i. & Matsui, T. Pigment epithelium-derived factor (PEDF) and
 cardiometabolic disorders. *Current pharmaceutical design* 20, 2377-2386 (2014).
- 1099 33 Yamagishi, S. & Matsui, T. Pigment epithelium-derived factor (PEDF) and 1100 cardiometabolic disorders. *Curr Pharm Des* **20**, 2377-2386,

- 1101 doi:10.2174/13816128113199990473 (2014).
- 110234Ma, S., Wang, S., Li, M., Zhang, Y. & Zhu, P. The effects of pigment1103epithelium-derived factor on atherosclerosis: putative mechanisms of the process.
- 1104 *Lipids Health Dis* **17**, 240, doi:10.1186/s12944-018-0889-z (2018).
- 1105 35 Zhang, J. *et al.* The role of aldehyde dehydrogenase 2 in cardiovascular disease. *Nat* 1106 *Rev Cardiol* 20, 495-509, doi:10.1038/s41569-023-00839-5 (2023).
- 1107 36 Chen, C. H., Sun, L. & Mochly-Rosen, D. Mitochondrial aldehyde dehydrogenase
 and cardiac diseases. *Cardiovasc Res* 88, 51-57, doi:10.1093/cvr/cvq192 (2010).
- 1109 37 Lee, J. Y. *et al.* A genome-wide association study of a coronary artery disease risk
 1110 variant. *J Hum Genet* 58, 120-126, doi:10.1038/jhg.2012.124 (2013).
- Islam, T., Rahman, M. R., Khan, A. & Moni, M. A. Integration of Mendelian
 randomisation and systems biology models to identify novel blood-based biomarkers
 for stroke. *J Biomed Inform* 141, 104345, doi:10.1016/j.jbi.2023.104345 (2023).
- 1114 39 Kuo, C. L. *et al.* The Longevity-Associated SH2B3 (LNK) Genetic Variant: Selected
 1115 Aging Phenotypes in 379,758 Subjects. *J Gerontol A Biol Sci Med Sci* 75, 1656-1662,
 1116 doi:10.1093/gerona/glz191 (2020).
- 1117 40 Goswami, S. K., Ranjan, P., Dutta, R. K. & Verma, S. K. Management of
 1118 inflammation in cardiovascular diseases. *Pharmacol Res* 173, 105912,
 1119 doi:10.1016/j.phrs.2021.105912 (2021).
- 1120 41 Nevers, T. *et al.* Th1 effector T cells selectively orchestrate cardiac fibrosis in nonischemic heart failure. *J Exp Med* 214, 3311-3329, doi:10.1084/jem.20161791
 1122 (2017).
- Flister, M. J. *et al.* SH2B3 Is a Genetic Determinant of Cardiac Inflammation and
 Fibrosis. *Circ Cardiovasc Genet* 8, 294-304, doi:10.1161/circgenetics.114.000527
 (2015).
- 1126 43 Zhu, X. *et al.* Exacerbating Pressure Overload-Induced Cardiac Hypertrophy: Novel
 1127 Role of Adaptor Molecule Src Homology 2-B3. *Hypertension* 66, 571-581,
 1128 doi:10.1161/hypertensionaha.115.05183 (2015).
- 112944Nassour, J., Schmidt, T. T. & Karlseder, J. Telomeres and Cancer: Resolving the1130Paradox.AnnuRevCancerBiol5, 59-77,


doi:10.1146/annurev-cancerbio-050420-023410 (2021).

- 1132 45 Zhang, S. *et al.* TMEM116 is required for lung cancer cell motility and metastasis
 1133 through PDK1 signaling pathway. *Cell Death Dis* 12, 1086,
 1134 doi:10.1038/s41419-021-04369-1 (2021).
- Sinner, M. F. *et al.* Integrating genetic, transcriptional, and functional analyses to
 identify 5 novel genes for atrial fibrillation. *Circulation* 130, 1225-1235,
 doi:10.1161/circulationaha.114.009892 (2014).
- Fuster, J. J. & Andrés, V. Telomere biology and cardiovascular disease. *Circ Res* 99, 1139
 1167-1180, doi:10.1161/01.Res.0000251281.00845.18 (2006).
- Minamino, T. *et al.* Endothelial cell senescence in human atherosclerosis: role of
 telomere in endothelial dysfunction. *Circulation* 105, 1541-1544,
 doi:10.1161/01.cir.0000013836.85741.17 (2002).
- 1143 49 Farzaneh-Far, R. *et al.* Telomere length trajectory and its determinants in persons with
 1144 coronary artery disease: longitudinal findings from the heart and soul study. *PLoS*1145 *One* 5, e8612, doi:10.1371/journal.pone.0008612 (2010).
- 1146 50 Bulik-Sullivan, B. K. *et al.* LD Score regression distinguishes confounding from
 1147 polygenicity in genome-wide association studies. *Nature genetics* 47, 291-295,
 1148 doi:10.1038/ng.3211 (2015).
- Bulik-Sullivan, B. *et al.* An atlas of genetic correlations across human diseases and
 traits. *Nature genetics* 47, 1236-1241, doi:10.1038/ng.3406 (2015).
- Frei, O. *et al.* Bivariate causal mixture model quantifies polygenic overlap between
 complex traits beyond genetic correlation. *Nature communications* 10, 2417,
 doi:10.1038/s41467-019-10310-0 (2019).
- 1154 53 O'Connor, L. J. & Price, A. L. Distinguishing genetic correlation from causation
 1155 across 52 diseases and complex traits. *Nature genetics* 50, 1728-1734,
 1156 doi:10.1038/s41588-018-0255-0 (2018).
- 1157 54 Darrous, L., Mounier, N. & Kutalik, Z. Simultaneous estimation of bi-directional
 1158 causal effects and heritable confounding from GWAS summary statistics. *Nature*1159 *communications* 12, 7274, doi:10.1038/s41467-021-26970-w (2021).
- 1160 55 Sanderson, E. et al. Mendelian randomization. Nat Rev Methods Primers 2,

1161 doi:10.1038/s43586-021-00092-5 (2022).

- Burgess, S., Scott, R. A., Timpson, N. J., Davey Smith, G. & Thompson, S. G. Using
 published data in Mendelian randomization: a blueprint for efficient identification of
 causal risk factors. *Eur J Epidemiol* **30**, 543-552, doi:10.1007/s10654-015-0011-z
 (2015).
- 1166 57 Bowden, J., Davey Smith, G. & Burgess, S. Mendelian randomization with invalid
 1167 instruments: effect estimation and bias detection through Egger regression. *Int J*1168 *Epidemiol* 44, 512-525, doi:10.1093/ije/dyv080 (2015).
- Hartwig, F. P., Davey Smith, G. & Bowden, J. Robust inference in summary data
 Mendelian randomization via the zero modal pleiotropy assumption. *Int J Epidemiol*46, 1985-1998, doi:10.1093/ije/dyx102 (2017).
- 1172 59 Ray, D. & Chatterjee, N. A powerful method for pleiotropic analysis under composite
 1173 null hypothesis identifies novel shared loci between Type 2 Diabetes and Prostate
 1174 Cancer. *PLoS genetics* 16, e1009218, doi:10.1371/journal.pgen.1009218 (2020).
- Watanabe, K., Taskesen, E., van Bochoven, A. & Posthuma, D. Functional mapping
 and annotation of genetic associations with FUMA. *Nature communications* 8, 1826,
 doi:10.1038/s41467-017-01261-5 (2017).
- Wang, K., Li, M. & Hakonarson, H. ANNOVAR: functional annotation of genetic
 variants from high-throughput sequencing data. *Nucleic Acids Res* 38, e164,
 doi:10.1093/nar/gkq603 (2010).
- Kircher, M. *et al.* A general framework for estimating the relative pathogenicity of
 human genetic variants. *Nature genetics* 46, 310-315, doi:10.1038/ng.2892 (2014).
- Boyle, A. P. *et al.* Annotation of functional variation in personal genomes using
 RegulomeDB. *Genome Res* 22, 1790-1797, doi:10.1101/gr.137323.112 (2012).
- Giambartolomei, C. *et al.* Bayesian test for colocalisation between pairs of genetic
 association studies using summary statistics. *PLoS genetics* 10, e1004383,
 doi:10.1371/journal.pgen.1004383 (2014).

1188




1189

Figure 1: Schematic representation of analyses performed for leukocyte telomere lengthand six major cardiovascular diseases in the current study.

1192 This figure demonstrates the comprehensive pleiotropic analysis conducted for LTL and six 1193 major CVDs from multiple perspectives within this study. We first investigated the shared 1194 genetic architectures between LTL and six major CVDs by assessing pairwise genetic overlap 1195 beyond correlation. Extensive analyses were then conducted to investigate two types of 1196 pleiotropy: horizontal pleiotropy, whereby causal variants for two traits colocalize in the same 1197 locus, and vertical pleiotropy, whereby a variant exerts an effect on one trait through another. 1198 Notably, spurious pleiotropy was excluded from the analysis, whereby causal variants for two 1199 traits fall into distinct loci but are in LD with a variant associated with both traits. Therefore, 1200 We applied Mendelian randomization to evaluate the pairwise causal associations between 1201 LTL and the CVDs, primarily elucidating the contributions from vertical pleiotropy. We used 1202 novel statistical tools to capture horizontal pleiotropy by characterizing the shared loci and

1203	their implications on genes, tissues, biological functions, and protein targets. This
1204	comprehensive pleiotropic analysis allowed us to construct an atlas of the shared genetic
1205	associations, enhancing our understanding of the complex interactions between LTL and
1206	cardiovascular health. The diagram was generated using BioRender (www.biorender.com) and
1207	has been included with permission for publication. LTL, leukocyte telomere length; AF, Atrial
1208	fibrillation; CAD, Coronary artery disease; VTE, Venous thromboembolism; HF, Heart failure;
1209	PAD, Peripheral artery disease.



1210

Figure 2: Genetic overlap between leukocyte telomere length and six major
cardiovascular diseases beyond genome-wide genetic correlation.

1213 (a) MiXeR-modeled genome-wide genetic overlap and genetic correlations (top right) and 1214 LAVA local correlations (bottom left) between LTL and six major CVDs. Top right: MiXeR 1215 Venn diagrams showing the number (in thousands) of estimated 'causal' variants that are 1216 unique to LTL (left circle), six major CVDs (non-overlapping part of the right circle) or 1217 shared between LTL and six major CVDs (overlapping part of circles). Genome-wide genetic 1218 correlation (r_g) and genetic correlation of shared variants (r_gs) are represented by the color of 1219 the trait-specific (r_g) and shared regions $(r_g s)$, respectively. The circle size represents the 1220 extent of polygenicity of each trait, with larger circles corresponding to greater polygenicity

1221	and vice versa. Bottom left: Volcano plots of LAVA local genetic correlation coefficients (rho,
1222	y-axis) against -log10 (p-values) for each pairwise analysis per locus. Larger dots with black
1223	circles represent significantly correlated loci after FDR correction (FDR < 0.05). MiXeR
1224	estimated r_g and r_{gs} , and LAVA estimated rho are represented on the same blue to red color
1225	scale. Note that the volcano plots were plotted at p-values truncated by $1 \square \times \square 10^{-F12}$ for better
1226	visualization, thus excluding a region (LD block 1,581 on chromosome 10, ranges from
1227	104,206,838 to 106,142,283) influencing LTL - CAD from volcano plots of LAVA. (b)
1228	Genetic correlation estimated by LDSC (x-axis) against the percentage of LTL variants that
1229	are shared with CVDs as estimated by MiXeR (first plot), the percentage of CVD variants
1230	that are shared with LTL (second plot), and the percentage of CVD variants that are shared
1231	with LTL that have concordant effect directions (third plot). The fourth plot shows the
1232	percentage of local genetic correlations from LAVA with concordant effect directions on the
1233	y-axis. LTL, leukocyte telomere length; AF, Atrial fibrillation; CAD, Coronary artery disease;
1234	VTE, Venous thromboembolism; HF, Heart failure; PAD, Peripheral artery disease.





Figure 3: Manhattan plots for the PLACO results of leukocyte telomere length and sixmajor cardiovascular diseases.

1235

The x-axis reflects the chromosomal position, and the y-axis reflects negative log10 1238 1239 transformed P-values for each SNP. The horizontal dashed red line indicates the genome-wide significant *P*-value of $-\log 10 (5 \times 10^{-8})$. The independent genome-wide significant associations 1240 1241 with the smallest P-value (Top lead SNP) are encircled in a colorful circle. Only SNPs shared 1242 across all summary statistics were included. Labels are the chromosome regions where 1243 genomic risk loci with strong evidence for colocalization (PP.H4 > 0.7) are located. LTL, 1244 leukocyte telomere length; AF, Atrial fibrillation; CAD, Coronary artery disease; VTE, 1245 Venous thromboembolism; HF, Heart failure; PAD, Peripheral artery disease.



1246

Figure 4: The Overall landscape of the pleiotropic associations across leukocyte telomere length and six msjor cardiovascular diseases.

1249 A circular dendrogram showing the shared genes between LTL (center circle) and each of six 1250 CVDs (first circle), resulting in six pairs. A total of 248 shared loci were identified across six 1251 trait pairs, mapped to 478 significant pleiotropic genes (323 unique) identified by multimarker 1252 analysis of GenoMic annotation (MAGMA). For the trait pairs with more than three 1253 pleiotropic genes, we only showed the top 3 pleiotropic genes according to the prioritization 1254 of candidate pleiotropic genes (fourth circle). LTL, leukocyte telomere length; AF, Atrial 1255 fibrillation; CAD, Coronary artery disease; VTE, Venous thromboembolism; HF, Heart failure; 1256 PAD, Peripheral artery disease.

1257






Figure 5: The results of multiple-tissue analysis using gene expression data and chromatin data for leukocyte telomere length and six cardiovascular diseases.

1261	(a) Tissue type-specific enrichment of single nucleotide polymorphism (SNP) heritability for
1262	LTL and CVDs in 49 tissues from GTEx v8 estimated using stratified LDSC applied to
1263	specifically expressed genes (LDSC-SEG). Each bar represents a tissue from the GTEx
1264	dataset. The x-axis reflects tissue types, and the y-axis reflects negative log10 transformed
1265	P-values. (b) Each point represents a peak for DNase I hypersensitivity site (DHS) or histone
1266	marks (including H3K27ac, H3K36me3, H3K4me1, H3K4me3, and H3K9ac) in a tissue or
1267	cell type. Tissues or cell types were classified into 11 distinct categories, i.e., 'Adipose,'
1268	'Blood/Immune,' 'Cardiovascular," 'CNS,' 'Digestive,' 'Endocrine,' 'Musculoskeletal/Skin,'
1269	'kidney,' 'Liver,' 'Respiratory,' and 'Other.' The black dotted line represents the significance
1270	threshold of $P < 0.05$, and the red line indicates the significant P-value after conducting FDR
1271	correction (FDR < 0.05). The color of the dots in a and b indicates different tissue types. LTL,
1272	leukocyte telomere length; AF, Atrial fibrillation; CAD, Coronary artery disease; VTE,
1273	Venous thromboembolism; HF, Heart failure; PAD, Peripheral artery disease.







(a) Volcano plots based on SMR showing circulating proteins (red, blue, or gray dots) with
the associations between circulating protein levels and each of the traits (x-axis) and the
corresponding P-value (y-axis). Red dots indicate positive causal relations. Blue dots indicate

1280 negative causal relations. Gray dots indicate insignificant causal relations. Protein-trait

- associations passing Bonferroni correction ($P < 2.60 \times 10-5$) are outlined in black. (b) Miami
- 1282 plots of the 12q24.12 region. Genes that were mapped under the locus at 12q24.12 were
- 1283 highlighted in the analysis. The protein SH2B3 is labeled as significantly associated with LTL,
- 1284 CAD, and VTE. The red horizontal dashed line corresponds to Bonferroni correction (P <
- 1285 2.60×10^{-5}). LTL, leukocyte telomere length; AF, Atrial fibrillation; CAD, Coronary artery
- 1286 disease; VTE, Venous thromboembolism; HF, Heart failure; PAD, Peripheral artery disease.

Figure1

medRxiv preprint doi: https://doi.org/10.1101/2024.05.20.24307614; this version posted May 23, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

Contribution of leukocyte telomere length to major cardiovascular diseases onset








Figure 2





























Chromosome 12 Mb